Pharmacodynamics of (-)-β-2',3'-dideoxy-3'-thiacytidine in chronically virus-infected woodchucks compared to its pharmacodynamics in humans

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 11, 1998, Pages 2804-2809

  Hurwitz, Selwyn J ^a   Tennant, Bud C ^b   Korba, Brent E ^c   Gerin, John L ^c   Schinazi, Raymond F ^a,d  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Animal Health Diagnostic Center   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

^d ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; VIRUS DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; FEMALE; HEPATITIS B VIRUS; HEPATITIS VIRUS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; VIRUS INFECTION; VIRUS LOAD; WOODCHUCK;

EID: 0031782844     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.11.2804     Document Type: Article

References (35)

1. Arts, E. J., and Wainberg, M. A. 1996. Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription. Antimicrob. Agents Chemother. 40:527-540.
2. Cammack, N., P. Rouse, C. L. P. Marr, P. J. Reid, R. E. Boehme, J. A. V. Coates, C. R. Penn, and J. M. Cameron. 1992. Cellular metabolism of (-) enantiomeric 2′-deoxy-3′-thiacytidine. Biochem. Pharmacol. 43:2059-2064.
3. Chang, C. N., S. L. Doong, J. H. Zhou, J. W. Beach, L. S. Jeong, C. K. Chu, C. H. Tsai, R. F. Schinazi, D. C. Liotta, and Y. C. Cheng. 1992. Deoxycytidine deaminase-resistant stereoisomer is the active form of (±)-2′,3′-dideoxy-3′-thiacytidine in the inhibition of hepatitis B virus replication. J. Biol. Chem. 267:13938-13942.
4. Fourel, I., J. M. Cullen, J. Saputelli, C. E. Aldrich, P. Schaffer, D. R. Averett, J. Pugh, and W. S. Mason. 1994. Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks. J. Virol. 68:8321-8330.
5. Gabrielsson, J., and D. Weiner. 1994. Pharmacokinetic and pharmacodynamic data analysis. Concepts and applications, p. 423-433. Swedish Pharmaceutical Press, Stockholm, Sweden.
6. Gibaldi, M., and D. Perrier. 1982. Pharmacokinetics, 2nd ed., p. 113-144. Marcel Dekker, Inc., New York, N.Y.
7. Honkoop, P., R. A. de Man, R. A. Heijtink, and S. W. Schalm. 1995. Hepatitis B reactivation after lamivudine. Lancet 346:1156-1157.
8. Hurwitz, S. J., B. Tennant, B. E. Korba, and R. F. Schinazi. 1997. Comparison of the viral pnarmacodynamics of 3TC in chronically infected woodchucks and humans. Antivir. Res. 34:A53. (Abstract 38.)
9. Kajino, K., A. R. Jilbert, J. Saputelli, C. E. Aldrich, J. Cullen, and W. S. Mason. 1994. Woodchuck hepatitis virus infections: very rapid recovery after a prolonged viremia and infection of virtually every hepatocyte. J. Virol. 68: 5792-5803.
10. Korba, B. E., H. Xie, K. N. Wright, W. E. Hornbuckle, J. L. Gerin, B. C. Tennant, and K. Y. Hostetler. 1996. Liver targeted antiviral nucleosides: enhanced antiviral activity of phosphatidyl-dideoxyguanosine versus didcoxyguanosine in woodchuck hepatitis in vivo. Hepatology 23:958-963.
11. Korba, B. E., F. Wells, B. C. Tennant, P. J. Cote, and J. L. Gerin. 1987. Lymphoid cells in the spleens of woodchuck hepatitis virus-infected woodchucks are a site of active viral replication. J. Virol. 61:1318-1324.
12. 11a. Locarnini, S. A. Personal communication.
13. Mason, W. S., and J. M. Taylor. 1989. Experimental systems for the study of hepadnavirus and delta virus infections. Hepatology 9:635-645.
14. Mason, W. W., D. Averett, J. Pugh, K. Kajino, J. Cullen, I. Fourel, and A. Jilbert. 1996. Antiviral therapy for chronic hepadnavirus infections. Antivir. Ther. 1(Suppl. 4):53-58.
15. Moore, K. H. P., G. J. Yuen, R. H. Raasch, J. J. Eron, D. Martin, P. K. Mydlow, and E. K. Hussey. 1996. Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole. Clin. Pharmacol. Ther. 59:550-558.
16. Newbold, J. E., H. Xin, M. Tencza, G. Sherman, J. Dean, S. Bowden, and S. Locarnini. 1995. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J. Virol. 69:3350-3357.
17. Nixon, F. E. 1965. Handbook of Laplace transformation. Fundamentals and application, tables and examples, 2nd ed. Prentice-Hall Applied Math Series. Prentice-Hall International, Inc., London, England.
18. Nowak, M. A., S. Bonhoeffer, A. M. Hill, R. Boehme, H. C. Thomas, and H. McDade. 1996. Viral dynamics in hepatitis B virus infection. Proc. Natl. Acad. Sci. USA 93:4398-4402.
19. Phillips, A. N. 1996. Reduction of HIV concentration during acute infection: independence from a specific immune response. Science 271:497-499.
20. Rajagopalan, P., F. D. Boudinot, C. K. Chu, B. C. Tennant, B. H. Baldwin, and R. F. Schinazi. 1996. Pharmacokinetics of (-)-2′-3′-dideoxy-3′-thiacytidine in woodchucks. Antimicrob. Agents Chemother. 40:642-645.
21. Ralston, M. L., and R. I. Jennrich. 1978. DUD, a derivative-free algorithm for nonlinear least squares. Technomerics 20:7-14.
22. Rivkin, M. B., J. M. Cullen, W. S. Robinson, and P. L. Marion. 1994. State of the p53 gene in hepatocellular carcinomas of ground squirrels and woodchucks with past and ongoing infection with hepadnaviruses. Cancer Res. 54: 5430-5437.
23. Roggendorf, M., and T. K. Tolle. 1995. The woodchuck: an animal model for hepatitis B virus infection in man. Intervirology 38:100-112.
24. Roth, L., J. M. King, W. E. Hornbuckle, H. J. Harvey, and B. C. Tennant. 1985. Chronic hepatitis and hepatocellular carcinoma associated with persistent woodchuck hepatitis virus infection. Vet. Pathol. 22:338-343.
25. SAS Institute Inc. 1990. The NLIN procedure, p. 1135-1193. In SAS/STAT users guide, vol. 2, GLM-VARCOMP, version 6, 4th ed. SAS Institute, Inc., Cary, N.C.
26. Schinazi, R. F. 1997. Impact of nucleosides on hepatitis viruses, p. 736-742. In M. Rizzeto, R. H. Purcell, J. L. Gerin, and G. Verme (ed.), Viral hepatitis and liver disease. Edizioni Minerva Medica, Turin, Italy.
27. Schinazi, R. F., L. Hough, A. Juodawlkis, P. Marion, and B. Tennant. 1997. Comparative activation of 2′-deoxycytidine and antiviral oxathiolane cytosine nucleosides by different mammalian liver extracts. Antivir. Res. 34:a65. (Abstract 84.)
28. Seeger, C., J. Summers, and W. S. Mason. 1991. Viral DNA synthesis. Curr. Top Microbiol. Immunol. 168:41-60.
29. Seeger, C., B. Baldwin, W. E. Hornbuckle, A. E. Yeager, B. C. Tennant, P. Cote, L. Ferrell, D. Ganem, and H. E. Varmus. 1991. Woodchuck hepatitis virus is a more efficient oncogenic agent than ground squirrel hepatitis virus in a common host. J. Virol. 65:1673-1679.
30. Shaw, T., and S. A. Locarnini. 1995. Hepatic purine and pyrimidine metabolism: implications for antiviral chemotherapy of viral hepatitis. Liver 15: 169-184.
31. Shewach, D. S., D. C. Liotta, and R. F. Schinazi. 1993. Affinity of the antiviral enantiomers of oxathiolane cytosine nucleosides for human 2′-deoxycytidine kinase. Biochem. Pharmacol. 45:1540-1543.
32. Summers, J., P. M. Smith, and A. L. Horwich. 1990. Hepadnavirus envelope proteins regulate covalently closed circular DNA amplification. J. Virol. 64: 2819-2824.
33. Suzuki, S., B. Lee, W. Luo, D. Tovell, M. J. Robins, and L. J. Tyrell. 1988. Inhibition of duck hepatitis B virus replication by purine 2′,3′-dideoxy nucleosides. Biochem. Biophys. Res. Commun. 156:1144-1151.
34. Tennant, B. C., B. H. Baldwin, L. A. Graham, M. A. Ascenzi, W. E. Hornbuckle, P. H. Rowland, I. A. Tochkov, A. E. Yeager, H. N. Erb, J. M. Colacino, C. Lopez, J. A. Engelhardt, R. R. Bowsher, F. C. Richardson, W. Lewis, P. J. Cote, B. E. Korba, and J. L. Gerin. Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection. Hepatology, in press.
35. Tiollias, P., C. Pourcel, and A. Dejean. 1985. The hepatitis B virus. Nature 317:489-495.